Alan I. Green - Publications

Affiliations: 
Pharmacology and Toxicology Dartmouth College, Hanover, NH, United States 

148 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Whitton AE, Green AI, Pizzagalli DA, Roth RM, Williams JM, Brunette MF. Potent Dopamine D2 Antagonists Block the Reward-Enhancing Effects of Nicotine in Smokers With Schizophrenia. Schizophrenia Bulletin. PMID 30690638 DOI: 10.1093/schbul/sby185  0.48
2018 Falk DE, Ryan ML, Fertig JB, Devine EG, Cruz R, Brown ES, Burns H, Salloum IM, Newport DJ, Mendelson J, Galloway G, Kampman K, Brooks C, Green AI, Brunette MF, et al. Gabapentin Enacarbil Extended-Release for Alcohol Use Disorder: A Randomized, Double-Blind, Placebo-Controlled, Multisite Trial assessing Efficacy and Safety. Alcoholism, Clinical and Experimental Research. PMID 30403402 DOI: 10.1111/acer.13917  0.48
2018 Doucette WT, Dwiel L, Boyce JE, Simon AA, Khokhar JY, Green AI. Machine Learning Based Classification of Deep Brain Stimulation Outcomes in a Rat Model of Binge Eating Using Ventral Striatal Oscillations. Frontiers in Psychiatry. 9: 336. PMID 30123143 DOI: 10.3389/fpsyt.2018.00336  1
2018 Khokhar JY, Henricks AM, Sullivan EDK, Green AI. Unique Effects of Clozapine: A Pharmacological Perspective. Advances in Pharmacology (San Diego, Calif.). 82: 137-162. PMID 29413518 DOI: 10.1016/bs.apha.2017.09.009  1
2017 Eisenberg IW, Bissett PG, Canning JR, Dallery J, Enkavi AZ, Whitfield-Gabrieli S, Gonzalez O, Green AI, Greene MA, Kiernan M, Kim SJ, Li J, Lowe MR, Mazza GL, Metcalf SA, et al. Applying novel technologies and methods to inform the ontology of self-regulation. Behaviour Research and Therapy. PMID 29066077 DOI: 10.1016/j.brat.2017.09.014  0.48
2017 Green AI, Khokhar JY. Addiction and schizophrenia: A translational perspective. Schizophrenia Research. PMID 29046253 DOI: 10.1016/j.schres.2017.10.008  1
2017 Whitfield-Gabrieli S, Fischer AS, Henricks AM, Khokhar JY, Roth RM, Brunette MF, Green AI. Understanding marijuana's effects on functional connectivity of the default mode network in patients with schizophrenia and co-occurring cannabis use disorder: A pilot investigation. Schizophrenia Research. PMID 28823723 DOI: 10.1016/j.schres.2017.07.029  1
2017 Khokhar JY, Dwiel LL, Henricks AM, Doucette WT, Green AI. The link between schizophrenia and substance use disorder: A unifying hypothesis. Schizophrenia Research. PMID 28416205 DOI: 10.1016/j.schres.2017.04.016  1
2016 Brunette MF, Akerman SC, Dawson R, O'Keefe CD, Green AI. An open-label pilot study of quetiapine plus mirtazapine for heavy drinkers with alcohol use disorder. Alcohol (Fayetteville, N.Y.). PMID 27256763 DOI: 10.1016/j.alcohol.2016.02.006  1
2016 Drake RE, Green AI. Illuminating the Interstices: What Small Studies Add to Science. Journal of Dual Diagnosis. 0. PMID 27070957 DOI: 10.1080/15504263.2016.1177374  1
2016 Drake RE, Green AI. Trauma, Technology, and Routine Outcome Measures. Journal of Dual Diagnosis. 0. PMID 26829002 DOI: 10.1080/15504263.2016.1147776  1
2016 Khokhar JY, Green AI. Effects of iloperidone, combined with desipramine, on alcohol drinking in the Syrian golden hamster. Neuropharmacology. 105: 25-34. PMID 26796639 DOI: 10.1016/j.neuropharm.2016.01.017  1
2015 Drake RE, Green AI. Progress in Dual Diagnosis Research: Innovation and Controlled Trials. Journal of Dual Diagnosis. 11: 151-2. PMID 26683250 DOI: 10.1080/15504263.2015.1116237  1
2015 Doucette WT, Khokhar JY, Green AI. Nucleus accumbens deep brain stimulation in a rat model of binge eating. Translational Psychiatry. 5: e695. PMID 26670280 DOI: 10.1038/tp.2015.197  1
2015 Chau DT, Khokhar JY, Gulick D, Dawson R, Green AI. Desipramine enhances the ability of paliperidone to decrease alcohol drinking. Journal of Psychiatric Research. 69: 9-18. PMID 26343589 DOI: 10.1016/j.jpsychires.2015.07.010  1
2015 Green AI, Brunette MF, Dawson R, Buckley P, Wallace AE, Hafez H, Herz M, Narasimhan M, Noordsy DL, O'Keefe C, Sommi RW, Steinbook RM, Weeks M. Long-acting injectable vs oral risperidone for schizophrenia and co-occurring alcohol use disorder: a randomized trial. The Journal of Clinical Psychiatry. PMID 26302441 DOI: 10.4088/JCP.13m08838  1
2015 Khokhar JY, Chau DT, Dawson R, Green AI. Clozapine reconstructed: Haloperidol's ability to reduce alcohol intake in the Syrian golden hamster can be enhanced through noradrenergic modulation by desipramine and idazoxan. Drug and Alcohol Dependence. 152: 277-81. PMID 25979645 DOI: 10.1016/j.drugalcdep.2015.04.003  1
2015 Drake RE, Green AI. A call for creativity in dual diagnosis research. Journal of Dual Diagnosis. 11: 93-6. PMID 25782138 DOI: 10.1080/15504263.2015.1027125  1
2015 Green AI, Drake RE. Subtyping and tailoring treatment approaches. Journal of Dual Diagnosis. 11: 1-2. PMID 25671682 DOI: 10.1080/15504263.2014.992557  1
2015 Akerman SC, Brunette MF, Green AI, Goodman DJ, Blunt HB, Heil SH. Treating tobacco use disorder in pregnant women in medication-assisted treatment for an opioid use disorder: a systematic review. Journal of Substance Abuse Treatment. 52: 40-7. PMID 25592332 DOI: 10.1016/j.jsat.2014.12.002  0.48
2015 Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Response to "cortico-accumbens circuitry in schizophrenia: merely a reward system?" by Rolland and Jardri (SCHRES-14-D-00731). Schizophrenia Research. 161: 519. PMID 25465412 DOI: 10.1016/j.schres.2014.10.008  1
2014 Akerman SC, Brunette MF, Noordsy DL, Green AI. Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders. Current Addiction Reports. 1: 251-260. PMID 27226947 DOI: 10.1007/s40429-014-0034-7  0.48
2014 Drake RE, Green AI. From the editors. Journal of Dual Diagnosis. 10: 107. PMID 25392283 DOI: 10.1080/15504263.2014.930268  1
2014 Drake RE, Green AI. From the editors. Journal of Dual Diagnosis. 10: 59. PMID 25392247 DOI: 10.1080/15504263.2014.906710  1
2014 Drake RE, Green AI. New awareness, new populations, new technologies, and new ideas. Journal of Dual Diagnosis. 10: 1-2. PMID 25392056 DOI: 10.1080/15504263.2013.869656  1
2014 Drake RE, Green AI. Developing innovative interventions for people with dual diagnosis. Journal of Dual Diagnosis. 10: 175-6. PMID 25391274 DOI: 10.1080/15504263.2014.969047  1
2014 Fischer AS, Whitfield-Gabrieli S, Roth RM, Brunette MF, Green AI. Impaired functional connectivity of brain reward circuitry in patients with schizophrenia and cannabis use disorder: Effects of cannabis and THC. Schizophrenia Research. 158: 176-82. PMID 25037524 DOI: 10.1016/j.schres.2014.04.033  1
2014 Gulick D, Chau DT, Khokhar JY, Dawson R, Green AI. Desipramine enhances the ability of risperidone to decrease alcohol intake in the Syrian golden hamster. Psychiatry Research. 218: 329-34. PMID 24836200 DOI: 10.1016/j.psychres.2014.04.038  1
2014 Mesholam-Gately RI, Gibson LE, Seidman LJ, Green AI. Schizophrenia and co-occurring substance use disorder: reward, olfaction and clozapine. Schizophrenia Research. 155: 45-51. PMID 24685823 DOI: 10.1016/j.schres.2014.03.002  1
2013 Chau DT, Khokhar JY, Dawson R, Ahmed J, Xie H, Green AI. The comparative effects of clozapine versus haloperidol on initiation and maintenance of alcohol drinking in male alcohol-preferring P rat. Alcohol (Fayetteville, N.Y.). 47: 611-8. PMID 24280363 DOI: 10.1016/j.alcohol.2013.10.002  1
2013 Litten RZ, Ryan ML, Fertig JB, Falk DE, Johnson B, Dunn KE, Green AI, Pettinati HM, Ciraulo DA, Sarid-Segal O, Kampman K, Brunette MF, Strain EC, Tiouririne NA, Ransom J, et al. A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence. Journal of Addiction Medicine. 7: 277-86. PMID 23728065 DOI: 10.1097/ADM.0b013e31829623f4  1
2013 Evins AE, Green AI, Kane JM, Murray RM. Does using marijuana increase the risk for developing schizophrenia? The Journal of Clinical Psychiatry. 74: e08. PMID 23656852 DOI: 10.4088/JCP.12012tx2c  1
2013 Gamsby JJ, Templeton EL, Bonvini LA, Wang W, Loros JJ, Dunlap JC, Green AI, Gulick D. The circadian Per1 and Per2 genes influence alcohol intake, reinforcement, and blood alcohol levels. Behavioural Brain Research. 249: 15-21. PMID 23608482 DOI: 10.1016/j.bbr.2013.04.016  1
2013 Fetter JC, Brunette M, Green AI. N-3 fatty acids for hypertriglyceridemia in patients taking second-generation antipsychotics. Clinical Schizophrenia & Related Psychoses. 7: 73-77A. PMID 23367502 DOI: 10.3371/CSRP.FEBR.012513  1
2013 Drake RE, Green AI. Is current dual diagnosis research sufficient Journal of Dual Diagnosis. 9: 269-270. DOI: 10.1080/15504263.2013.836416  1
2013 Drake RE, Green AI. The challenge of heterogeneity and complexity in dual diagnosis Journal of Dual Diagnosis. 9: 105-106. DOI: 10.1080/15504263.2013.779104  1
2013 Green AI. Approaching polypharmacy Journal of Dual Diagnosis. 9: 219. DOI: 10.1080/15504263.2013.778190  1
2013 Drake RE, Green AI. Will the complexities of dual diagnosis be addressed by health care reform? Journal of Dual Diagnosis. 9: 1-2. DOI: 10.1080/15504263.2012.750852  1
2012 Evins AE, Green AI, Kane JM, Murray RM. The effect of marijuana use on the risk for schizophrenia. The Journal of Clinical Psychiatry. 73: 1463-8. PMID 23218162 DOI: 10.4088/JCP.12012co1c  1
2012 Fertig JB, Ryan ML, Falk DE, Litten RZ, Mattson ME, Ransom J, Rickman WJ, Scott C, Ciraulo D, Green AI, Tiouririne NA, Johnson B, Pettinati H, Strain EC, Devine E, et al. A double-blind, placebo-controlled trial assessing the efficacy of levetiracetam extended-release in very heavy drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 1421-30. PMID 22324516 DOI: 10.1111/j.1530-0277.2011.01716.x  1
2012 Litten RZ, Fertig JB, Falk DE, Ryan ML, Mattson ME, Collins JF, Murtaugh C, Ciraulo D, Green AI, Johnson B, Pettinati H, Swift R, Afshar M, Brunette MF, Tiouririne NA, et al. A double-blind, placebo-controlled trial to assess the efficacy of quetiapine fumarate XR in very heavy-drinking alcohol-dependent patients. Alcoholism, Clinical and Experimental Research. 36: 406-16. PMID 21950727 DOI: 10.1111/j.1530-0277.2011.01649.x  1
2012 Drake RE, Green AI. On silos, moieties, and health care reform Journal of Dual Diagnosis. 8: 169-170. DOI: 10.1080/15504263.2012.698145  1
2012 Green AI. Long-acting injectable antipsychotic medications in patients with comorbid schizophrenia and substance use disorders Journal of Dual Diagnosis. 8: 62-63. DOI: 10.1080/15504263.2012.647506  1
2011 Brunette MF, Dawson R, O'Keefe CD, Narasimhan M, Noordsy DL, Wojcik J, Green AI. A randomized trial of clozapine vs. other antipsychotics for cannabis use disorder in patients with schizophrenia. Journal of Dual Diagnosis. 7: 50-63. PMID 25914610 DOI: 10.1080/15504263.2011.570118  1
2011 Chau DT, Ahmed J, Wang TT, Xie H, Dawson R, Green AI. Raclopride lessens the ability of clozapine to suppress alcohol drinking in Syrian golden hamsters. Neuropharmacology. 61: 646-52. PMID 21619888 DOI: 10.1016/j.neuropharm.2011.05.007  1
2011 Green AI, Drake RE. Perspectives on treatment Journal of Dual Diagnosis. 7: 115-116. DOI: 10.1080/15504263.2011.593414  1
2011 Green AI, Drake RE. Current epidemiology and emerging interventions for people with co-occurring mental illness and substance use disorders Journal of Dual Diagnosis. 7: 1-3. DOI: 10.1080/15504263.2011.571624  1
2010 Gulick D, Green AI. Role of caloric homeostasis and reward in alcohol intake in Syrian golden hamsters. Physiology & Behavior. 101: 518-26. PMID 20688091 DOI: 10.1016/j.physbeh.2010.07.019  1
2010 Henderson MB, Green AI, Bradford PS, Chau DT, Roberts DW, Leiter JC. Deep brain stimulation of the nucleus accumbens reduces alcohol intake in alcohol-preferring rats. Neurosurgical Focus. 29: E12. PMID 20672914 DOI: 10.3171/2010.4.FOCUS10105  1
2010 Chau DT, Gulick D, Xie H, Dawson R, Green AI. Clozapine chronically suppresses alcohol drinking in Syrian golden hamsters. Neuropharmacology. 58: 351-6. PMID 19895824 DOI: 10.1016/j.neuropharm.2009.10.006  1
2010 Green AI, Drake RE. Journal of Dual Diagnosis: From the editors Journal of Dual Diagnosis. 6: 189-191. DOI: 10.1080/15504263.2010.540774  1
2009 Nasrallah HA, Keshavan MS, Benes FM, Braff DL, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. The Journal of Clinical Psychiatry. 70: 4-46. PMID 19292973 DOI: 10.4088/JCP.8157su1c.01  1
2009 Whitfield-Gabrieli S, Thermenos HW, Milanovic S, Tsuang MT, Faraone SV, McCarley RW, Shenton ME, Green AI, Nieto-Castanon A, LaViolette P, Wojcik J, Gabrieli JD, Seidman LJ. Hyperactivity and hyperconnectivity of the default network in schizophrenia and in first-degree relatives of persons with schizophrenia. Proceedings of the National Academy of Sciences of the United States of America. 106: 1279-84. PMID 19164577 DOI: 10.1073/pnas.0809141106  1
2009 Brunette MF, Dawson R, O'Keefe C, Buckley P, Green AI. An open label study of quetiapine in patients with schizophrenia and alcohol disorders Mental Health and Substance Use: Dual Diagnosis. 2: 203-211. DOI: 10.1080/17523280903156073  1
2009 Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: A randomized, double-blind trial of olanzapine versus haloperidol (American Journal of Psychiatry (2003) 160, (1396-1404)) American Journal of Psychiatry. 166: 942.  1
2008 Riggs P, Levin F, Green AI, Vocci F. Comorbid psychiatric and substance abuse disorders: recent treatment research. Substance Abuse. 29: 51-63. PMID 19042206 DOI: 10.1080/08897070802218794  1
2008 Dawson R, Green AI, Drake RE, McGlashan TH, Schanzer B, Lavori PW. Developing and testing adaptive treatment strategies using substance-induced psychosis as an example. Psychopharmacology Bulletin. 41: 51-67. PMID 18779776  1
2008 Wang JF, Min JY, Hampton TG, Amende I, Yan X, Malek S, Abelmann WH, Green AI, Zeind J, Morgan JP. Clozapine-induced myocarditis: role of catecholamines in a murine model. European Journal of Pharmacology. 592: 123-7. PMID 18627770 DOI: 10.1016/j.ejphar.2008.06.088  1
2008 Green AI, Noordsy DL, Brunette MF, O'Keefe C. Substance abuse and schizophrenia: pharmacotherapeutic intervention. Journal of Substance Abuse Treatment. 34: 61-71. PMID 17574793 DOI: 10.1016/j.jsat.2007.01.008  1
2008 Brunette MF, O'Keefe C, Zimmet S, Wojcik J, Dawson R, Brownell E, Green AI. Clozapine, olanzapine, or typical antipsychotics for alcohol use disorder in patients with schizophrenia Journal of Dual Diagnosis. 4: 344-354. DOI: 10.1080/15504260802313816  1
2007 Dunayevich E, Ascher-Svanum H, Zhao F, Jacobson JG, Phillips GA, Dellva MA, Green AI. Longer time to antipsychotic treatment discontinuation for any cause is associated with better functional outcomes for patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder. The Journal of Clinical Psychiatry. 68: 1163-71. PMID 17854239  1
2007 Green AI. Pharmacotherapy for schizophrenia and co-occurring substance use disorders. Neurotoxicity Research. 11: 33-40. PMID 17449446 DOI: 10.1007/BF03033480  1
2007 Green AI, Drake RE, Brunette MF, Noordsy DL. Schizophrenia and co-occurring substance use disorder. The American Journal of Psychiatry. 164: 402-8. PMID 17329463 DOI: 10.1176/appi.ajp.164.3.402  1
2007 Altamura AC, Mundo E, Bassetti R, Green A, Lindenmayer JP, Alphs L, Meltzer HY. Transcultural differences in suicide attempters: analysis on a high-risk population of patients with schizophrenia or schizoaffective disorder. Schizophrenia Research. 89: 140-6. PMID 17097854 DOI: 10.1016/j.schres.2006.08.023  1
2007 Green AI. Substance abuse and schizophrenia: Pharmacological approaches Journal of Dual Diagnosis. 3: 63-72. DOI: 10.1300/J374v03n02_08  1
2006 Green AI, Brown ES. Comorbid schizophrenia and substance abuse. The Journal of Clinical Psychiatry. 67: e08. PMID 17081075 DOI: 10.4088/JCP.0906e08  1
2006 Green AI. Treatment of schizophrenia and comorbid substance abuse: pharmacologic approaches. The Journal of Clinical Psychiatry. 67: 31-5; quiz 36-7. PMID 16961422  1
2006 Drake RE, Green AI. Current research on co-occurring substance-use disorder in schizophrenia. Schizophrenia Bulletin. 32: 616-7. PMID 16896056 DOI: 10.1093/schbul/sbl020  1
2006 Green AI, Lieberman JA, Hamer RM, Glick ID, Gur RE, Kahn RS, McEvoy JP, Perkins DO, Rothschild AJ, Sharma T, Tohen MF, Woolson S, Zipursky RB. Olanzapine and haloperidol in first episode psychosis: two-year data. Schizophrenia Research. 86: 234-43. PMID 16887334 DOI: 10.1016/j.schres.2006.06.021  1
2006 McHugo GJ, Drake RE, Brunette MF, Xie H, Essock SM, Green AI. Enhancing validity in co-occurring disorders treatment research. Schizophrenia Bulletin. 32: 655-65. PMID 16849398 DOI: 10.1093/schbul/sbl009  1
2006 Brunette MF, Drake RE, Xie H, McHugo GJ, Green AI. Clozapine use and relapses of substance use disorder among patients with co-occurring schizophrenia and substance use disorders. Schizophrenia Bulletin. 32: 637-43. PMID 16782758 DOI: 10.1093/schbul/sbl003  1
2006 Perkins DO, Johnson JL, Hamer RM, Zipursky RB, Keefe RS, Centorrhino F, Green AI, Glick IB, Kahn RS, Sharma T, Tohen M, McEvoy JP, Weiden PJ, Lieberman JA. Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode. Schizophrenia Research. 83: 53-63. PMID 16529910 DOI: 10.1016/j.schres.2005.10.016  1
2006 Lindsey MA, Korr WS, Broitman M, Bone L, Green A, Leaf PJ. Help-seeking behaviors and depression among African American adolescent boys Social Work. 51: 49-58. PMID 16512510  1
2005 Zipursky RB, Gu H, Green AI, Perkins DO, Tohen MF, McEvoy JP, Strakowski SM, Sharma T, Kahn RS, Gur RE, Tollefson GD, Lieberman JA. Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol. The British Journal of Psychiatry : the Journal of Mental Science. 187: 537-43. PMID 16319406 DOI: 10.1192/bjp.187.6.537  1
2005 Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, Montoya I, Parks J, Weiss RD. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. Journal of Psychiatric Practice. 11: 315-39. PMID 16184072 DOI: 10.1097/00131746-200509000-00005  1
2005 Green AI. Schizophrenia and comorbid substance use disorder: effects of antipsychotics. The Journal of Clinical Psychiatry. 66: 21-6. PMID 16107180  1
2005 Roth RM, Brunette MF, Green AI. Treatment of substance use disorders in schizophrenia: a unifying neurobiological mechanism? Current Psychiatry Reports. 7: 283-91. PMID 16098282  1
2005 Niznikiewicz MA, Patel JK, McCarley R, Sutton J, Chau DT, Wojcik J, Green AI. Clozapine action on auditory P3 response in schizophrenia. Schizophrenia Research. 76: 119-21. PMID 15927806 DOI: 10.1016/j.schres.2004.11.012  1
2005 Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS, Keefe RS, Green AI, Gur RE, McEvoy J, Perkins D, Hamer RM, Gu H, Tohen M. Antipsychotic drug effects on brain morphology in first-episode psychosis. Archives of General Psychiatry. 62: 361-70. PMID 15809403 DOI: 10.1001/archpsyc.62.4.361  1
2005 Brunette MF, Noordsy DL, Buckley PF, Green AI. Pharmacologic treatments for co-occurring substance use disorders in patients with schizophrenia: A research review Journal of Dual Diagnosis. 1: 41-55. DOI: 10.1300/J374v01n02_04  1
2005 Green AI. Journal of Dual Diagnosis: Editorial Journal of Dual Diagnosis. 1: 7-9. DOI: 10.1300/J374v01n02_02  1
2005 Drake RE, Brunette MF, Mueser KT, Green AI. Management of patients with severe mental illness and co-occurring substance use disorder Minerva Psichiatrica. 46: 119-132.  1
2005 Cimpean D, Torrey WC, Green AI. Schizophrenia and co-occurring general medical illness Psychiatric Annals. 35: 71-81.  1
2004 Alphs L, Anand R, Islam MZ, Meltzer HY, Kane JM, Krishnan R, Green AI, Potkin S, Chouinard G, Lindenmayer JP, Kerwin R. The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. Schizophrenia Bulletin. 30: 577-86. PMID 15631247  1
2004 Green AI, Chau DT, Keung WM, Dawson R, Mesholam RI, Schildkraut JJ. Clozapine reduces alcohol drinking in Syrian golden hamsters. Psychiatry Research. 128: 9-20. PMID 15450910 DOI: 10.1016/j.psychres.2004.05.005  1
2004 Chau DT, Roth RM, Green AI. The neural circuitry of reward and its relevance to psychiatric disorders. Current Psychiatry Reports. 6: 391-9. PMID 15355762  1
2004 Perkins DO, Lieberman JA, Gu H, Tohen M, McEvoy J, Green AI, Zipursky RB, Strakowski SM, Sharma T, Kahn RS, Gur R, Tollefson G. Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders British Journal of Psychiatry. 185: 18-24. PMID 15231551 DOI: 10.1192/bjp.185.1.18  1
2004 Elman I, Rott D, Green AI, Langleben DD, Lukas SE, Goldstein DS, Breier A. Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia. Psychopharmacology. 176: 369-75. PMID 15179540 DOI: 10.1007/s00213-004-1890-y  1
2004 Le Fauve CE, Litten RZ, Randall CL, Moak DH, Salloum IM, Green AI. Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcoholism, Clinical and Experimental Research. 28: 302-12. PMID 15112938 DOI: 10.1097/01.ALC.0000113413.37910.D7  1
2004 Green AI, Tohen MF, Hamer RM, Strakowski SM, Lieberman JA, Glick I, Clark WS. First episode schizophrenia-related psychosis and substance use disorders: acute response to olanzapine and haloperidol. Schizophrenia Research. 66: 125-35. PMID 15061244 DOI: 10.1016/j.schres.2003.08.001  1
2003 Drake RE, Green AI, Mueser KT, Goldman HH. The history of community mental health treatment and rehabilitation for persons with severe mental illness. Community Mental Health Journal. 39: 427-40. PMID 14635985 DOI: 10.1023/A:1025860919277  1
2003 Lieberman JA, Tollefson G, Tohen M, Green AI, Gur RE, Kahn R, McEvoy J, Perkins D, Sharma T, Zipursky R, Wei H, Hamer RM. Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. The American Journal of Psychiatry. 160: 1396-404. PMID 12900300 DOI: 10.1176/appi.ajp.160.8.1396  1
2003 Lindenmayer JP, Czobor P, Alphs L, Nathan AM, Anand R, Islam Z, Chou JC. The InterSePT scale for suicidal thinking reliability and validity. Schizophrenia Research. 63: 161-70. PMID 12892870 DOI: 10.1016/S0920-9964(02)00335-3  1
2003 Stone WS, Seidman LJ, Wojcik JD, Green AI. Glucose effects on cognition in schizophrenia. Schizophrenia Research. 62: 93-103. PMID 12765749 DOI: 10.1016/S0920-9964(02)00406-1  1
2003 Green AI, Canuso CM, Brenner MJ, Wojcik JD. Detection and management of comorbidity in patients with schizophrenia. The Psychiatric Clinics of North America. 26: 115-39. PMID 12683263 DOI: 10.1016/S0193-953X(02)00014-X  1
2003 Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophrenia Research. 60: 81-5. PMID 12505141 DOI: 10.1016/S0920-9964(02)00231-1  1
2003 Potkin SG, Alphs L, Hsu C, Krishnan KRR, Anand R, Young FK, Meltzer H, Green A, Altinsan S, Altman S, Avigo L, Balon R, Benešová V, Bengochea L, Bitter I, et al. Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial Biological Psychiatry. 54: 444-452. DOI: 10.1016/S0006-3223(03)00178-1  1
2003 Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S, Altinsan S, Altman S, et al. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT) Archives of General Psychiatry. 60: 82-91. DOI: 10.1001/archpsyc.60.1.82  1
2003 Noordsy DL, Green AI. Pharmacotherapy for schizophrenia and co-occuring substance use disorders Current Psychiatry Reports. 5: 340-346.  1
2002 Green AI, Salomon MS, Brenner MJ, Rawlins K. Treatment of schizophrenia and comorbid substance use disorder. Current Drug Targets. Cns and Neurological Disorders. 1: 129-39. PMID 12769622  1
2002 Canuso CM, Goldstein JM, Wojcik J, Dawson R, Brandman D, Klibanski A, Schildkraut JJ, Green AI. Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Research. 111: 11-20. PMID 12140115 DOI: 10.1016/S0165-1781(02)00123-3  1
2002 Elman I, Goldstein DS, Green AI, Eisenhofer G, Folio CJ, Holmes CS, Pickar D, Breier A. Effects of risperidone on the peripheral noradrenegic system in patients with schizophrenia: a comparison with clozapine and placebo. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 27: 293-300. PMID 12093603 DOI: 10.1016/S0893-133X(02)00314-7  1
2002 Patel JK, Wong E, Green AI. Drugs of abuse Side Effects of Drugs Annual. 25: 34-46. DOI: 10.1016/S0378-6080(02)80011-3  1
2001 Stone WS, Faraone SV, Seidman LJ, Green AI, Wojcik JD, Tsuang MT. Concurrent validation of schizotaxia: a pilot study. Biological Psychiatry. 50: 434-40. PMID 11566160 DOI: 10.1016/S0006-3223(01)01116-7  1
2001 Faraone SV, Green AI, Seidman LJ, Tsuang MT. "Schizotaxia": clinical implications and new directions for research. Schizophrenia Bulletin. 27: 1-18. PMID 11215539  1
2001 Patel JK, Caplan B, Green A, Tamminga C. First-episode psychosis: Critical management issues during the first two years Harvard Review of Psychiatry. 9: 33-41. PMID 11159931  1
2000 Green AI. What is the relationship between schizophrenia and substance abuse? The Harvard Mental Health Letter / From Harvard Medical School. 17: 8. PMID 11015759  1
2000 Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. General Hospital Psychiatry. 22: 224-35. PMID 10936629 DOI: 10.1016/S0163-8343(00)00081-5  1
2000 Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophrenia Bulletin. 26: 441-9. PMID 10885642  1
2000 Green AI, Tohen M, Patel JK, Banov M, DuRand C, Berman I, Chang H, Zarate C, Posener J, Lee H, Dawson R, Richards C, Cole JO, Schatzberg AF. Clozapine in the treatment of refractory psychotic mania. The American Journal of Psychiatry. 157: 982-6. PMID 10831480 DOI: 10.1176/appi.ajp.157.6.982  1
2000 Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. Journal of Clinical Psychopharmacology. 20: 94-8. PMID 10653215 DOI: 10.1097/00004714-200002000-00016  1
1999 Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Review of Psychiatry. 6: 287-96. PMID 10370435  1
1999 Strous RD, Patel JK, Zimmet S, Green AI. Clozapine and paroxetine in the treatment of schizophrenia with obsessive-compulsive features. The American Journal of Psychiatry. 156: 973-4. PMID 10360153  1
1999 Tsuang MT, Stone WS, Seidman LJ, Faraone SV, Zimmet S, Wojcik J, Kelleher JP, Green AI. Treatment of nonpsychotic relatives of patients with schizophrenia: four case studies. Biological Psychiatry. 45: 1412-8. PMID 10356622 DOI: 10.1016/S0006-3223(98)00364-3  1
1998 Canuso CM, Goldstein JM, Green AI. The evaluation of women with schizophrenia. Psychopharmacology Bulletin. 34: 271-7. PMID 9803753  1
1998 Canuso CM, Hanau M, Jhamb KK, Green AI. Olanzapine use in women with antipsychotic-induced hyperprolactinemia. The American Journal of Psychiatry. 155: 1458. PMID 9766782  1
1998 Berman I, Merson A, Viegner B, Losonczy MF, Pappas D, Green AI. Obsessions and compulsions as a distinct cluster of symptoms in schizophrenia: a neuropsychological study. The Journal of Nervous and Mental Disease. 186: 150-6. PMID 9521350 DOI: 10.1097/00005053-199803000-00003  1
1997 Patel JK, Green AI, Kalinowski A, Tsuang MT. Evaluation of a complex case: the value of a drug washout period. The American Journal of Psychiatry. 154: 1747-50. PMID 9396956  1
1997 Kando JC, Shepski JC, Satterlee W, Patel JK, Reams SG, Green AI. Olanzapine: a new antipsychotic agent with efficacy in the management of schizophrenia. The Annals of Pharmacotherapy. 31: 1325-34. PMID 9391688  1
1997 Lyons MJ, Toomey R, Meyer JM, Green AI, Eisen SA, Goldberg J, True WR, Tsuang MT. How do genes influence marijuana use? The role of subjective effects. Addiction (Abingdon, England). 92: 409-17. PMID 9177062  1
1997 Berman I, Viegner B, Merson A, Allan E, Pappas D, Green AI. Differential relationships between positive and negative symptoms and neuropsychological deficits in schizophrenia. Schizophrenia Research. 25: 1-10. PMID 9176922 DOI: 10.1016/S0920-9964(96)00098-9  1
1997 Patel JK, Salzman C, Green AI, Tsuang MT. Chronic schizophrenia: response to clozapine, risperidone, and paroxetine. The American Journal of Psychiatry. 154: 543-6. PMID 9090343  1
1995 Green AI, Schildkraut JJ. Should clozapine be a first-line treatment for schizophrenia? The rationale for a double-blind clinical trial in first-episode patients. Harvard Review of Psychiatry. 3: 1-9. PMID 9384923 DOI: 10.3109/10673229509017159  1
1995 Berman I, Kalinowski A, Berman SM, Lengua J, Green AI. Obsessive and compulsive symptoms in chronic schizophrenia. Comprehensive Psychiatry. 36: 6-10. PMID 7705089 DOI: 10.1016/0010-440X(95)90092-A  1
1995 Berman I, Sapers BL, Chang HH, Losonczy MF, Schmildler J, Green AI. Treatment of obsessive-compulsive symptoms in schizophrenic patients with clomipramine. Journal of Clinical Psychopharmacology. 15: 206-10. PMID 7635998 DOI: 10.1097/00004714-199506000-00009  1
1994 Albanese MJ, Khantzian EJ, Murphy SL, Green AI. Decreased substance use in chronically psychotic patients treated with clozapine. The American Journal of Psychiatry. 151: 780-1. PMID 8166327  1
1994 Green AI, Zalma A, Berman I, DuRand CJ, Salzman C. Clozapine following ECT: a two-step treatment. The Journal of Clinical Psychiatry. 55: 388-90. PMID 7929018  1
1993 Green AI, Austin CP. Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics. 34: 208-21. PMID 8493302 DOI: 10.1016/S0033-3182(93)71882-4  1
1993 Green AI, Alam MY, Sobieraj JT, Pappalardo KM, Waternaux C, Salzman C, Schatzberg AF, Schildkraut JJ. Clozapine response and plasma catecholamines and their metabolites. Psychiatry Research. 46: 139-49. PMID 8483973 DOI: 10.1016/0165-1781(93)90016-A  1
1993 Green AI, Alam MY, Boshes RA, Waternaux C, Pappalardo KM, Fitzgibbon ME, Tsuang MT, Schildkraut JJ. Haloperidol response and plasma catecholamines and their metabolites. Schizophrenia Research. 10: 33-7. PMID 8369230 DOI: 10.1016/0920-9964(93)90074-S  1
1993 Seidman LJ, Pepple JR, Faraone SV, Kremen WS, Green AI, Brown WA, Tsuang MT. Neuropsychological performance in chronic schizophrenia in response to neuroleptic dose reduction. Biological Psychiatry. 33: 575-84. PMID 8101100 DOI: 10.1016/0006-3223(93)90095-U  1
1992 DuRand CJ, Jaretz NJ, Laddis A, Berman I, Green AI. Clozapine refusal. Hospital & Community Psychiatry. 43: 85. PMID 1544662  1
1992 Berman I, Zalma A, DuRand CJ, Green AI. Clozapine-induced myoclonic jerks and drop attacks. The Journal of Clinical Psychiatry. 53: 329-30. PMID 1517198  1
1992 Holinger DP, Faux SF, Shenton ME, Sokol NS, Seidman LJ, Green AI, McCarley RW. Reversed temporal region asymmetries of P300 topography in left- and right-handed schizophrenic subjects. Electroencephalography and Clinical Neurophysiology. 84: 532-7. PMID 1280199 DOI: 10.1016/0168-5597(92)90042-A  1
1991 Reich JH, Green AI. Effect of personality disorders on outcome of treatment. The Journal of Nervous and Mental Disease. 179: 74-82. PMID 1990074  1
1990 Green AI, Salzman C. Clozapine: benefits and risks. Hospital & Community Psychiatry. 41: 379-80. PMID 2158938  1
1990 Green AI, Faraone SV, Brown WA. Prolactin shifts after neuroleptic withdrawal. Psychiatry Research. 32: 213-9. PMID 1975101 DOI: 10.1016/0165-1781(90)90026-2  1
1989 Green AI, Bennett MB, Salzman C. An extramural training program in psychopharmacology: one model for a state system. Hospital & Community Psychiatry. 40: 126-7. PMID 2914665  1
1989 Faraone SV, Green AI, Brown W, Yin P, Tsuang MT. Neuroleptic dose reduction in persistently psychotic patients. Hospital & Community Psychiatry. 40: 1193-5. PMID 2572532  1
1988 Green AI, Brown WA. Prolactin and neuroleptic drugs. Neurologic Clinics. 6: 213-23. PMID 2898095  1
1988 Green AI, Brown WA. Prolactin and neuroleptic drugs. Endocrinology and Metabolism Clinics of North America. 17: 213-23. PMID 2897910  1
1987 Green AI, Salzman C. Social drugs Side Effects of Drugs Annual. 11: 31-36. DOI: 10.1016/S0378-6080(87)80009-0  1
1986 Salzman C, Green AI, Rodriguez-Villa F, Jaskiw GI. Benzodiazepines combined with neuroleptics for management of severe disruptive behavior. Psychosomatics. 27: 17-22. PMID 3952250  1
1984 Green AI. Thyroid function and affective disorders. Hospital & Community Psychiatry. 35: 1188-9. PMID 6439621  1
1970 Kuhar MJ, Green AI, Snyder SH, Gfeller E. Separation of synaptosomes storing catecholamines and gamma-aminobutyric acid in rat corpus striatum. Brain Research. 21: 405-17. PMID 5456733 DOI: 10.1016/0006-8993(70)90420-8  0.88
1970 Snyder SH, Kuhar MJ, Green AI, Coyle JT, Shaskan EG. Uptake and Subcellular Localization of Neurotransmitters in the Brain International Review of Neurobiology. 13: 127-158. DOI: 10.1016/S0074-7742(08)60168-3  0.88
1969 Green AI, Snyder SH, Iversen LL. Separation of catecholamine-storing synaptosomes in different regions of rat brain. The Journal of Pharmacology and Experimental Therapeutics. 168: 264-71. PMID 5803310  0.88
1968 Snyder SH, Green AI, Hendley ED. Kinetics of H3-norepinephrine accumulation into slices from different regions of the rat brain. The Journal of Pharmacology and Experimental Therapeutics. 164: 90-102. PMID 5722109  0.88
Show low-probability matches.